PLx Pharma Inc (PLXP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:PLx Pharma Inc (PLXP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013957
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PLx Pharma Inc (PLx Pharma) is a drug development company that develops patent-protected delivery systems. The company’s products include PLxGuard delivery system, PLxGuard pipeline products, PL2200 aspirin and PL1100 and PL1200 ibuprofen products. Its PLxGuard delivery system are used in enhancement of efficacy of drugs, GI safety development, new or extended patent protection, and new drug application solutions. PLx Pharma offers publications and research services. The company serves for severe pain and cardiovascular market. It caters its products and services to healthcare professionals. PLx Pharma is headquartered in Houston, Texas, the US.

PLx Pharma Inc (PLXP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PLx Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PLx Pharma Inc, Medical Devices Deals, 2011 to YTD 2017 10
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
PLx Pharma Raises USD1.3 Million in Venture Financing 12
PLx Pharma Raises USD9 Million in Extended Series E Financing 13
PLx Pharma Raises USD8.27 Million in Series E Financing 14
PLx Pharma Secures US$2.9 Million In Series F Round 15
Merger 16
Dipexium Pharma Merges with PLx Pharma 16
Licensing Agreements 18
PLx Pharma Enters into Licensing Agreement with Lee’s Pharma for Cardiovascular Product 18
Equity Offering 19
PLx Pharma Raises USD18.2 Million in Private Placement of Shares 19
PLx Pharma Withdraws IPO 20
PLx Pharma Inc – Key Competitors 22
PLx Pharma Inc – Key Employees 23
PLx Pharma Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Nov 09, 2017: PLx Pharma Reports Third Quarter 2017 Results 25
Aug 10, 2017: PLx Pharma Reports Second Quarter 2017 Results 27
May 02, 2017: Rita M. O Connor Appointed Chief Financial Officer of PLx Pharma 28
Corporate Communications 29
May 01, 2017: PLx Pharma appoints vice president of sales and marketing 29
Jan 04, 2016: PLx Pharma Appoints Natasha Giordano as CEO 30
Product News 31
06/20/2016: Dipexium Pharmaceuticals Locilex Microbiology Data Presented at ASM Microbe 2016 Conference 31
05/10/2017: PLx Pharma Receives NCI Grant for Research of Novel Aspirin Formulation to Prevent Colorectal Cancer 32
05/01/2017: PLx Pharma Appoints Michael J. Dillon as Vice President, Sales and Marketing 33
Product Approvals 34
Oct 04, 2016: Dipexium Receives European Medicines Agency Designation as a Small and Medium Enterprise 34
Clinical Trials 35
Feb 14, 2017: PLx Pharma Announces Publication of Positive Antiplatelet Data for Aspertec in Peer-Reviewed Medical Journal JACC 35
Oct 25, 2016: Dipexium Announces Top-line Data from OneStep Phase 3 Trials with Locilex in Mild Diabetic Foot Infection Did Not Meet Primary Clinical Endpoint of Superiority Versus Vehicle Plus Standardized Wound Care 36
Oct 20, 2016: Dipexium Provides Update on Availability of Results from Pivotal Phase 3 Clinical Trials with Locilex 37
May 16, 2016: Dipexium Announces Completion of Enrollment Objective in OneStep-1 Pivotal Phase 3 Clinical Trial 38
May 12, 2016: Dipexium Pharmaceuticals Announces Completion of Enrollment Objective in OneStep-2 Pivotal Phase 3 Clinical Trial 39
Feb 04, 2016: Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
PLx Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2014 2
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PLx Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PLx Pharma Inc, Deals By Therapy Area, 2011 to YTD 2017 9
PLx Pharma Inc, Medical Devices Deals, 2011 to YTD 2017 10
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
PLx Pharma Raises USD1.3 Million in Venture Financing 12
PLx Pharma Raises USD9 Million in Extended Series E Financing 13
PLx Pharma Raises USD8.27 Million in Series E Financing 14
PLx Pharma Secures US$2.9 Million In Series F Round 15
Dipexium Pharma Merges with PLx Pharma 16
PLx Pharma Enters into Licensing Agreement with Lee's Pharma for Cardiovascular Product 18
PLx Pharma Raises USD18.2 Million in Private Placement of Shares 19
PLx Pharma Withdraws IPO 20
PLx Pharma Inc, Key Competitors 22
PLx Pharma Inc, Key Employees 23

★海外企業調査レポート[PLx Pharma Inc (PLXP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • EQT Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    EQT Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary EQT Corp (EQT) is an integrated oil and gas company. It operates production fields in Marcellus, Upper Devonian, Ohio Utica and other plays in Appalachian Basin. The company produces and markets natural gas …
  • China Suntien Green Energy Co Ltd (956):企業の財務・戦略的SWOT分析
    China Suntien Green Energy Co Ltd (956) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Crescent Point Energy Corp (CPG):石油・ガス:M&Aディール及び事業提携情報
    Summary Crescent Point Energy Corp (Crescent Point) is an oil and gas company. It acquires, explores, develops and produces light and medium crude oil, heavy crude oil, tight oil, natural gas liquids, shale gas and conventional natural gas. The company holds interest in light and medium oil and natu …
  • Incyte Corp (INCY):製薬・医療:M&Aディール及び事業提携情報
    Summary Incyte Corp (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycyt …
  • Quantum Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Quantum Pharma Ltd (Quantum Pharma), a subsidiary Clinigen Group Plc, is a manufacturer and supplier of unlicensed medicines. The company develops, manufactures, and supplies niche pharmaceutical products. It offers dermatology products, branded generics and vitamins, borderline substances, …
  • DPR Construction, Inc.:企業の戦略・SWOT・財務情報
    DPR Construction, Inc. - Strategy, SWOT and Corporate Finance Report Summary DPR Construction, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • China Evergrande Group:企業のM&A・事業提携・投資動向
    China Evergrande Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Evergrande Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Enel SpA (ENEL):企業の財務・戦略的SWOT分析
    Enel SpA (ENEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Medpace Inc (MEDP):企業の財務・戦略的SWOT分析
    Summary Medpace Inc (Medpace), a subsidiary of Medpace Holdings Inc is a contract research organization that develops research based drug and medical device. The organization provides services such as medical affairs, regulatory affairs and medical writing, clinical monitoring, clinical trial manage …
  • Cue Health Inc:企業の製品パイプライン分析2018
    Summary Cue Health Inc (Cue Health) is a healthcare technology company that strives to design, develop, manufacture and commercialize medical diagnostic products for use in home and clinical settings. The company’s lead product, Cue Health Monitoring System, is a connected diagnostic platform that h …
  • SoftBank Group Corporation:企業のM&A・事業提携・投資動向
    SoftBank Group Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SoftBank Group Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • CSS Industries, Inc. (CSS):企業の財務・戦略的SWOT分析
    CSS Industries, Inc. (CSS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • AutoGenomics Inc-医療機器分野:企業M&A・提携分析
    Summary AutoGenomics Inc (AutoGenomics) is a provider of automated technologies for test processes inherent in genetic analysis. The company offers infiniti systems and FDA cleared products and RUO products. Its infiniti system is designed for processing AutoGenomics' unique proprietary BioFilmChip …
  • Pulsion Medical Systems SE (PUS):医療機器:M&Aディール及び事業提携情報
    Summary Pulsion Medical Systems SE (Pulsion Medical Systems), formerly Pulsion Medical Systems AG, a subsidiary of Getinge AB, is a medical device company that manufactures and develops critical care systems and monitors. The company’s products include ProAQT sensor, PiCCO catheter, CeVOX module, Pi …
  • Gabather AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Gabather AB (Gabather) is a developer of new drug candidates for the treatment of central nervous system diseases. The company spans its expertise in the development of anti-psychotics, anti-depressants and anxiolytics, analgesics, and cognition-enhancing treatments. It offers drug candidate …
  • GS Yuasa Corporation:企業の戦略・SWOT・財務分析
    GS Yuasa Corporation - Strategy, SWOT and Corporate Finance Report Summary GS Yuasa Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Symrise AG (SY1):製薬・医療:M&Aディール及び事業提携情報
    Summary Symrise AG (Symrise) offers flavors and fragrances. The company develops, produces and sells flavorings, fragrances, cosmetic active ingredients and raw materials, and functional ingredients and solutions for the cosmetics industry. It also provides biofunctional and bioactive ingredients an …
  • Itochu Techno-Solutions Corp (4739):企業の財務・戦略的SWOT分析
    Itochu Techno-Solutions Corp (4739) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Anadolubank A.S.:企業の戦略・SWOT・財務情報
    Anadolubank A.S. - Strategy, SWOT and Corporate Finance Report Summary Anadolubank A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Kwality Group
    Kwality Group - Strategy, SWOT and Corporate Finance Report Summary Kwality Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆